Pharmacological mechanism of roflumilast in the treatment of asthma-COPD overlap

被引:21
作者
Zhang, Xiaoli [1 ]
Chen, Yuqing [1 ]
Fan, Liyu [1 ]
Ye, Jiaqi [1 ]
Fan, Junsheng [2 ]
Xu, Xinjie [1 ]
You, Danming [3 ]
Liu, Sihan [3 ]
Chen, Xin [1 ]
Luo, Peng [1 ]
机构
[1] Southern Med Univ, Zhujiang Hosp, Dept Resp Med, Guangzhou, Guangdong, Peoples R China
[2] Tongji Univ, Shanghai Peoples Hosp 10, Dept Resp Med, Shanghai, Peoples R China
[3] Southern Med Univ, Nangfang Hosp, Dept Resp Med, Guangzhou, Guangdong, Peoples R China
来源
DRUG DESIGN DEVELOPMENT AND THERAPY | 2018年 / 12卷
关键词
asthma-COPD overlap; roflumilast; phosphodiesterase-4; inhibitors; mechanism; OBSTRUCTIVE PULMONARY-DISEASE; PHOSPHODIESTERASE-4; INHIBITOR; SYNDROME ACOS; AIRWAY HYPERRESPONSIVENESS; EFFICACY FINDINGS; PDE4; METAANALYSIS; SUPPRESSION; SAFETY; MODEL;
D O I
10.2147/DDDT.S165161
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
Asthma-COPD overlap (ACO) is a type of incomplete obstructive airway disease that has a high incidence and mortality. Nevertheless, there is currently no clear definition of ACO and no effective intervention. The newly discovered phosphodiesterase-4 inhibitor, roflumilast, has shown initial efficacy for treating asthma, COPD, and ACO. The mechanism of roflumilast, however, remains unclear, and there has been no interpretation through systematic review to date. The determination of a definite mechanism of roflumilast will guide the clinician's decisions regarding medication use, standardized diagnosis, and treatment guidelines. For this reason, we have systematically reviewed the therapeutic mechanism of roflumilast for ACO and provided reference for the clinical application of roflumilast in ACO.
引用
收藏
页码:2371 / 2379
页数:9
相关论文
共 56 条
[1]  
[Anonymous], 2017, GLOB STRAT ASTHM MAN
[2]  
[Anonymous], COCHRANE DATABASE SY
[3]  
[Anonymous], EUR RESP J
[4]   Asthma-chronic obstructive pulmonary disease overlap syndrome - Literature review and contributions towards a Portuguese consensus [J].
Araujo, D. ;
Padrao, E. ;
Morais-Almeida, M. ;
Cardoso, J. ;
Pavao, F. ;
Leite, R. B. ;
Caldas, A. C. ;
Marques, A. .
REVISTA PORTUGUESA DE PNEUMOLOGIA, 2017, 23 (02) :90-99
[5]   Roflumilast for asthma: Efficacy findings in mechanism of action studies [J].
Bardin, P. ;
Kanniess, F. ;
Gauvreau, G. ;
Bredenbroeker, D. ;
Rabe, K. F. .
PULMONARY PHARMACOLOGY & THERAPEUTICS, 2015, 35 :S4-S10
[6]  
Barnes Neil C, 2007, Prim Care Respir J, V16, P149, DOI 10.3132/pcrj.2007.00038
[7]   Implementing lessons learned from previous bronchial biopsy trials in a new randomized controlled COPD biopsy trial with roflumilast [J].
Barnes, Neil C. ;
Saetta, Marina ;
Rabe, Klaus F. .
BMC PULMONARY MEDICINE, 2014, 14
[8]  
Barnette M S, 1999, Prog Drug Res, V53, P193
[9]   The asthma - chronic obstructive pulmonary disease overlap syndrome (ACOS): opportunities and challenges [J].
Barrecheguren, Miriam ;
Esquinas, Cristina ;
Miravitlles, Marc .
CURRENT OPINION IN PULMONARY MEDICINE, 2015, 21 (01) :74-79
[10]   Roflumilast for asthma: Efficacy findings in non-placebo-controlled comparator and dosing studies [J].
Bateman, E. D. ;
Bousquet, J. ;
Aubier, M. ;
Bredenbroeker, D. ;
O'Byrne, P. M. .
PULMONARY PHARMACOLOGY & THERAPEUTICS, 2015, 35 :S11-S19